MHRA
- Local brand name: Ibrance
- Status: approved
🇬🇧 Palbociclib in United Kingdom
NICE has issued 1 UK HTA decision
Marketing authorisation
Health technology assessment
1 decision from NICE for Palbociclib in United Kingdom.
NICE TA836 — ✓ Recommended
- Indication assessed: NICE technology appraisal guidance 836
NICE recommended Palbociclib for a specific indication. The decision was made based on the drug's clinical effectiveness and value for money. No restriction or condition was placed on the recommendation.
Palbociclib in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Palbociclib approved in United Kingdom?
Yes. MHRA has authorised it.
Who is the marketing authorisation holder for Palbociclib in United Kingdom?
Pfizer Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.
Has Palbociclib been assessed by UK health technology agencies?
Yes — 1 UK HTA decision on record from NICE.